FENNEC PHARMACEUTICALS INC.

Fennec Pharmaceuticals Inc. announced the grant of 10,000 incentive stock options (ISOs) to a new non-executive employee on June 10, 2026. These ISOs, granted under the 2026 Equity Inducement Plan, have an exercise price of $9.00 per share and a ten-year term. The options vest one-third on the one-year anniversary of the grant date and monthly thereafter over 24 months, contingent on continued employment.

Fennec Pharmaceuticals announced that new research evaluating PEDMARK (sodium thiosulfate injection) will be shared at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Four independently led studies expand the understanding of PEDMARK 's clinical utility in Adolescent and Young Adult (AYA) and adult populations, building on its established safety and efficacy. The research highlights the potential for PEDMARK to address cisplatin-induced ototoxicity more broadly and integrate into patient care without compromising antitumor activity.

Fennec Pharmaceuticals announced that new research evaluating PEDMARK® (sodium thiosulfate injection) will be shared at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. These four independently led studies expand the understanding of PEDMARK's clinical utility in Adolescent and Young Adult (AYA) and adult populations, building upon its established safety and efficacy in pediatric patients. The research includes a Phase 1 trial design for metastatic germ cell tumors, detailed results from a Japanese Phase 2/3 trial showing significant reduction in hearing loss, and real-world evidence demonstrating feasibility and hearing preservation in AYA and adult patients with various solid tumors.

Fennec Pharmaceuticals announced the grant of stock option awards for 50,000 common shares to three new non-executive employees. These options were approved by the Compensation Committee on May 11, 2026, with a grant date of May 18, 2026, under the 2026 Equity Inducement Plan. The exercise price is $9.75 per share, and the options vest over three years, starting one year from the grant date, subject to continued employment.

Fennec Pharmaceuticals reported a net income of $201 thousand for the first quarter of 2026, a significant improvement from a net loss of $1,165 thousand in the prior year. This turnaround was driven by a 72.6% increase in PEDMARK product sales, reaching $15.1 million. The company also generated positive cash flow from operating activities of $2.4 million, compared to a negative cash flow in the same period last year, and ended the quarter with $40.2 million in cash and cash equivalents.

Fennec Pharmaceuticals reported strong first-quarter 2026 financial results, with total net revenues increasing 73% year-over-year to $15.1 million and achieving a net income of $0.2 million, compared to a net loss in the prior year. The company highlighted continued growth in PEDMARK® adoption, positive early results from its field sales expansion, and the initiation of a third institution-led clinical study for PEDMARK®. Additionally, four abstracts evaluating PEDMARK® will be presented at the 2026 ASCO Annual Meeting.

Fennec Pharmaceuticals Inc. announced it will release its first quarter 2026 financial results on Thursday, May 14, 2026, before the U.S. financial markets open. Following the release, management will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial and business results. The company, a commercial stage specialty pharmaceutical firm, focuses on commercializing PEDMARK® to reduce ototoxicity in cancer patients.

Fennec Pharmaceuticals Inc. announced that Rostislav Raykov will retire from its Board of Directors, effective immediately following the 2026 annual meeting of shareholders. His departure is not due to any disagreement with the company. Concurrently, the Board has decided to reduce its size from six to five directors, effective after the Annual Meeting, with no expected vacancies.

Fennec Pharmaceuticals Inc. announced its Annual Meeting of Shareholders will be held virtually on June 10, 2026. Shareholders will vote on setting the board size at five and electing five directors, noting the departure of Mr. Rostislav Raykov. Other proposals include the appointment of auditors, advisory votes on executive compensation and its frequency, and approving an increase in shares reserved for the 2020 Equity Incentive Plan to 10,000,000, along with adopting a new 2026 Equity Inducement Plan.

Fennec Pharmaceuticals announced that four abstracts evaluating its drug PEDMARK® (sodium thiosulfate injection) were accepted for presentation or publication at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. This highlights growing clinical interest in addressing cisplatin-induced hearing loss, which PEDMARK aims to treat. The presentations will take place from May 29 to June 2, 2026, in Chicago.